These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10023941)

  • 1. Modest effect of interferon alfa on metastatic renal-cell carcinoma.
    Amato R
    Lancet; 1999 Jan; 353(9146):6-7. PubMed ID: 10023941
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.
    Lancet; 1999 Jan; 353(9146):14-7. PubMed ID: 10023944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
    Kirkali Z
    Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytokine therapy for metastatic renal cell carcinoma.
    Bukowski RM
    Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
    Flanigan RC; Salmon SE; Blumenstein BA; Bearman SI; Roy V; McGrath PC; Caton JR; Munshi N; Crawford ED
    N Engl J Med; 2001 Dec; 345(23):1655-9. PubMed ID: 11759643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemo-immunotherapy in RCC: the end of a story.
    Escudier B
    Lancet; 2010 Feb; 375(9715):613-4. PubMed ID: 20171385
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.
    Reddy K
    Clin Genitourin Cancer; 2006 Jun; 5(1):23-5. PubMed ID: 16859575
    [No Abstract]   [Full Text] [Related]  

  • 9. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg J
    Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cytokine therapy for metastatic renal cell carcinoma].
    Eto M; Naito S
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In focus: bevacizumab for renal cell carcinoma.
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
    Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
    J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alfa therapy against metastatic iris tumor of renal cell carcinoma.
    Ikeda T; Sato K; Tokuyama T
    Arch Ophthalmol; 2000 Jun; 118(6):846-7. PubMed ID: 10865325
    [No Abstract]   [Full Text] [Related]  

  • 14. Effective therapy for metastatic renal cancer, whither to now.
    Stadler WM
    J Clin Oncol; 2009 Aug; 27(22):3573-4. PubMed ID: 19487371
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolving treatment landscape in metastatic renal cell carcinoma: where are we now?
    Procopio G; Ratta R; Grassi P
    Expert Rev Anticancer Ther; 2016; 16(2):133-5. PubMed ID: 26654053
    [No Abstract]   [Full Text] [Related]  

  • 16. Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions.
    Royston P; Sauerbrei W; Ritchie A
    Br J Cancer; 2004 Feb; 90(4):794-9. PubMed ID: 14970855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen.
    Huland E; Heinzer H
    Br J Cancer; 2000 Jan; 82(1):246-7. PubMed ID: 10638997
    [No Abstract]   [Full Text] [Related]  

  • 18. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon for metastatic renal cell cancer causing regression of hereditary hemorrhagic telangiectasia.
    Wheatley-Price P; Shovlin C; Chao D
    J Clin Gastroenterol; 2005 Apr; 39(4):344-5. PubMed ID: 15758631
    [No Abstract]   [Full Text] [Related]  

  • 20. The current status of interferon-alpha treatment in advanced renal cancer.
    Stebbing J; Gore M
    BJU Int; 2001 May; 87(7):599-601. PubMed ID: 11350396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.